Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: Results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

Annals of the Rheumatic Diseases

Volumn 70, Issue 5, 2011, Pages 877-878

  Arts, E E A ^a   Jansen, T L ^b   Den Broeder, A ^c   Vonkeman, H E ^d   Dutmer, E ^e   Van De Laar, M A F J ^d   Van Riel, P L C M ^a   Fransen, J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL CENTER LEEUWARDEN   (Netherlands)

^c Maartenskliniek ^*  (Netherlands)

^d UNIVERSITY OF TWENTE   (Netherlands)

^e GELDERSE VALLEI HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; METHOTREXATE; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INFUSION; FEMALE; HUMAN; LETTER; MALE; NETHERLANDS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; RHEUMATOID ARTHRITIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 79953325909     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.136093     Document Type: Letter

References (9)

1. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008;359:613-26.
2. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary effi cacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. (Pubitemid 44497758)
3. Winiarska M, Bil J, Wilczek E, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008;5:e64.
4. Goldstein MR, Mascitelli L, Pezzetta F. Monoclonal antibody therapy and non- Hodgkin's lymphoma. N Engl J Med 2009;360:192; author reply 193.
5. Rabinowitz I. Interaction between statins and rituximab in non-Hodgkin's lymphoma. J Clin Oncol 2008;26:5486; author reply 5486.
6. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002;107:176-82. (Pubitemid 35279043)
7. Janas E, Priest R, Wilde JI, et al. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium infl ux and apoptosis. Clin Exp Immunol 2005;139:439-46. (Pubitemid 40333255)
8. Nowakowski GS, Maurer MJ, Habermann TM, et al. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 2010;28:412-17.
9. Samaras P, Heider H, Haile SR, et al. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Ann Hematol 2010;89:783-7.